Ortin Laboratories Limited [ORTINLAB.NS] Stock Forecast

Ortin Laboratories Limited manufactures and trades in pharmaceuticals, drugs, and intermediates in India. The company offers various pharmaceutical formulations of tablets, capsules, syrups, and dry powders. It provides formulations, such as anti diabetics, anti allergics, sedatives and tranquilisers, anti helmenthetics, analgesics and antipyretics, anti biotics-quinolones, anti biotic-pencillins, antifungal, cephalosporins, and macrolides; and anti anginal and cardio vascular, and antifungal products. The company's formulations also include chemo therapeutics, antacids and anti ulcerants, anti spasmodics, calcium preparations, iron preparations, anti arthritic drugs, protein supplements, enzymes, and vitamins, as well as psychiatry, appetizer, gynaec, and anti retroviral products. In addition, it provides active pharmaceutical ingredient (API) intermediates comprising anti retro viral, anti diabetics, analgesics and antipyretics, anti biotic, antifungal, antacids and anti ulcerants, and anti malarials; and manufactures fine chemicals, and grignard and alkali metal products. Further, the company offers services in the areas of process development, process characterization, analytical research and development, assay development, and product characterization; and diagnostic services, including development of rapid flow kits, assays, and reagents. Additionally, it undertakes long-term contracts for manufacturing intermediates and developing new APIs; and operates as a merchant exporter of pharmaceutical finished formulations. Ortin Laboratories Limited was incorporated in 1986 and is headquartered in Hyderabad, India.